Efficacy of dacarbazine (DTIC) in preventing metastases arising from intraocular melanomas in mice
Related Experiment Videos
G E Sanborn1, J Y Niederkorn, J W Gamel
1Virginia Eye Institute, Richmond.
Abstract:
At present there are no chemotherapeutic agents that have been proven to be effective in either preventing or retarding the progression of metastases arising from uveal melanomas in human subjects. Dacarbazine (DTIC), the single most effective chemotherapeutic agent in the treatment of cutaneous melanoma, is a potentially useful therapeutic modality for use as an antimetastatic agent in uveal melanoma. However, DTIC has not been evaluated for its ability to impede metastases originating from intraocular melanomas. The present study assessed the antimetastatic efficacy of DTIC in a murine intraocular melanoma model. The results indicate that treatment with DTIC resulted in sharp reductions in the number of spontaneous metastases and a significant prolongation of survival time. Dose-response studies indicated that exceedingly high doses of DTIC were necessary to produce antimetastatic effects even when drug treatment was combined with the calcium channel blocker verapamil. Collectively, the results indicate that DTIC can be an effective adjunctive therapeutic agent when administered at the time of enucleation of the melanoma-containing eye but is ineffectual if administered subsequent to surgery.
Insights
Dacarbazine (DTIC) effectively reduced metastases and prolonged survival in a murine uveal melanoma model. Optimal efficacy required high doses and administration during eye removal, not post-surgery.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacology
Background:
- No current chemotherapies prevent or slow uveal melanoma metastasis.
- Dacarbazine (DTIC) is effective for cutaneous melanoma but unstudied for uveal melanoma metastasis.
Purpose of the Study:
- To evaluate the antimetastatic efficacy of Dacarbazine (DTIC) in a murine intraocular melanoma model.
- To assess DTIC's potential as an antimetastatic agent for uveal melanoma.
Main Methods:
- Utilized a murine intraocular melanoma model to test DTIC's antimetastatic effects.
- Conducted dose-response studies, including combinations with verapamil.
- Administered DTIC at different time points relative to tumor enucleation.
Main Results:
- DTIC treatment significantly reduced spontaneous metastases.
- DTIC administration led to a significant prolongation of survival time.
- High DTIC doses were required for antimetastatic effects, even with verapamil.
Conclusions:
- DTIC shows potential as an adjunctive therapy for uveal melanoma metastasis.
- Effective DTIC administration requires concurrent timing with melanoma-containing eye enucleation.
- Post-surgical DTIC administration was ineffectual in preventing metastasis.